Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Indications for iris reconstruction surgery

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Cataract Complications & Special Cases

Venue: Poster Village: Pod 1

First Author: : J.Riedl GERMANY

Co Author(s): :    H. Biwer   U. Vossmerbaeumer                    

Abstract Details

Purpose:

Iris defects may result from blunt and penetrating injury, extreme IOP spikes as well as from genetic conditions. With the advent of microsurgical implants, novel therapeutic options for iris repair have become available. The distribution of indications for the application of is analysed in a 5 year series of a university eye centre.

Setting:

Retrospective clinical case series of the Department of Ophthalmologie, University Hospital Mainz

Methods:

50 patients who underwent pupil reconstruction surgery were analysed as to initial pathology, cause of trauma, concomitant ocular disease and preoperative visual function.

Results:

There are several reasons for the indication for an Artificial Iris ™ like traumatic mydriasis, traumatic iris defect, traumatic aniridia, congenital aniridia and Axenfeld-Rieger syndrome. While the majority of the patients suffered from a traumatic partial or complete aniridia, the minority showed congenital disorders. Surgery was not performed for merely cosmetic reasons for paediatric patients under 12 years of age and was not deemed effective in cases of prephthisis.

Conclusions:

The implantation of the artificial iris is an effective therapeutic option for the treatment of traumatic or congenital iris defects. We will demonstrate different cases for the implantation of an artificial iris and their results. The versatility of the implant allowing sector implantation, fixation in the sulcus or at the sclera and potential combination with IOL implantation makes a broad range of indications feasible.

Financial Disclosure:

None

Back to previous